艾迪药业：抗艾滋病领域在研1类新药ADC118片获准开展临床试验

Core Viewpoint - The company, Aidi Pharmaceutical, has received approval from the National Medical Products Administration for clinical trials of its new drug ADC118 in the field of HIV treatment, marking a significant milestone in its research and development efforts [1] Company Summary - Aidi Pharmaceutical's revenue composition for the year 2024 is as follows: 71.59% from pharmaceutical manufacturing, 27.07% from biopharmaceutical raw materials, 0.8% from medical devices, and 0.54% from other businesses [1] - As of the report date, Aidi Pharmaceutical has a market capitalization of 6.1 billion yuan [1] Industry Summary - The A-share market has recently surpassed 4000 points, indicating a resurgence after a decade of stagnation, with technology leading the market's transformation into a new "slow bull" pattern [1]